Literature DB >> 11709778

Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges.

R S Peebles1, K Hashimoto, R D Collins, K Jarzecka, J Furlong, D B Mitchell, J R Sheller, B S Graham.   

Abstract

Severe respiratory syncytial virus (RSV) infection has been hypothesized to be a risk factor for the development of allergy and asthma, but epidemiologic studies in humans have been inconclusive. By use of a well-characterized murine model of RSV infection and allergic sensitization with ovalbumin, the effect of a preceding severe RSV infection on the development of the pulmonary allergic inflammatory response and airway hyperresponsiveness (AHR) was tested. The impact of prior allergic sensitization on RSV-induced illness, as measured by weight loss, also was evaluated. RSV infection before allergic sensitization decreased allergen-induced AHR, production of interleukin-13 in lung tissue, and lung eosinophilia. In contrast, allergic sensitization before RSV infection increased AHR and decreased RSV-related weight loss and lung levels of interferon-gamma but did not alter viral clearance. These data provide evidence that RSV-associated AHR occurs in hosts with allergic responses and that allergic inflammation is diminished when preceded by RSV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709778     DOI: 10.1086/324429

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  The role of chemokines in virus-associated asthma exacerbations.

Authors:  Lara E Kallal; Nicholas W Lukacs
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 4.  The expanding role(s) of eosinophils in health and disease.

Authors:  Elizabeth A Jacobsen; Richard A Helmers; James J Lee; Nancy A Lee
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

5.  Respiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration.

Authors:  Sihyug Jang; Joost Smit; Lara E Kallal; Nicholas W Lukacs
Journal:  J Leukoc Biol       Date:  2013-01-04       Impact factor: 4.962

6.  Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.

Authors:  Rik L De Swart; Thijs Kuiken; Helga H Timmerman; Geert van Amerongen; Bernadette G Van Den Hoogen; Helma W Vos; Herman J Neijens; Arno C Andeweg; Albert D M E Osterhaus
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Development of atopy by severe paramyxoviral infection in a mouse model.

Authors:  Dorothy S Cheung; Sarah J Ehlenbach; Tom Kitchens; Desire A Riley; Mitchell H Grayson
Journal:  Ann Allergy Asthma Immunol       Date:  2010-12       Impact factor: 6.347

8.  Respiratory syncytial virus and reactive airway disease.

Authors:  Matthew T Lotz; Martin L Moore; R Stokes Peebles
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 9.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

10.  Neonatal respiratory syncytial virus infection has an effect on lung inflammation and the CD4(+) CD25(+) T cell subpopulation during ovalbumin sensitization in adult mice.

Authors:  A Comas-García; C P López-Pacheco; E A García-Zepeda; G Soldevila; P Ramos-Martínez; J Ramos-Castañeda
Journal:  Clin Exp Immunol       Date:  2016-05-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.